Ignite Creation Date:
2024-05-06 @ 7:17 AM
Last Modification Date:
2024-10-26 @ 11:46 AM
Study NCT ID:
NCT02504645
Status:
COMPLETED
Last Update Posted:
2019-04-11
First Post:
2015-07-17
Brief Title:
A 52-Week Randomized Double-Blind Parallel-Group Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Sponsor:
ImmuPharma
Organization:
ImmuPharma
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-03
Start Date Type:
ACTUAL
Primary Completion Date:
2018-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-01
Completion Date Type:
ACTUAL
First Submit Date:
2015-07-17
First Submit QC Date:
July 21 2015
Study First Post Date:
2015-07-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2019-04-11
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-04-10
Last Update Post Date:
2019-04-11
Last Update Post Date Type:
ACTUAL